KOD

Business Context and Reporting Period

Kodiak Sciences Inc. (KOD) is a pre-commercial, retina-focused biotechnology company developing transformative therapeutics for retinal diseases. The company operates as a single segment and is currently in the clinical stage of drug development with no products approved for commercial sale. This summary covers the quarterly period ended March 31, 2026.

Key Financial Metrics

Material Changes vs. Prior Period

• R&D Expenses: Increased by $4.9 million (11.2%) year-over-year. This was driven by a $6.6 million increase in KSI-501 program expenses and a $6.1 million increase in KSI-101 program expenses due to ramping clinical activities. These increases were partially offset by a $4.3 million decrease in tarcocimab expenses due to reduced manufacturing costs and the completion of the GLOW2 trial.
• G&A Expenses: Decreased by $4.2 million (27.2%) year-over-year. Reductions were attributed to lower stock-based compensation, reduced net rent expense following a sublease of a Palo Alto facility, and the absence of a $1.9 million non-cash lease impairment expense recorded in Q1 2025.
• Liquidity: Cash and cash equivalents decreased by approximately $40.3 million during the quarter, primarily due to operating cash burn. Total cash, cash equivalents, and restricted cash stood at $175.7 million as of March 31, 2026.
• Stock-Based Compensation: Total expense decreased to $12.2 million from $15.9 million in the prior year, reflecting the vesting of older, higher-value awards.

Guidance, Outlook, and Risks

Going Concern: Management has stated there is substantial doubt regarding the company's ability to continue as a going concern. The company believes existing cash resources may not be sufficient to meet anticipated operating and capital expenditure requirements for the 12 months following the report date. Additional capital will be required through equity or debt financings, collaborations, or other transactions.

Clinical Pipeline Updates:

• Zenkuda (tarcocimab): Completed four successful Phase 3 pivotal studies (GLOW1, GLOW2, BEACON, DAYLIGHT). The Phase 3 DAYBREAK study in wet AMD has completed enrollment, with topline data expected in Q3 2026. The company intends to file a Biologics License Application (BLA) in 2026.
• KSI-501: A bispecific therapy in the Phase 3 DAYBREAK study (wet AMD). Enrollment is complete; topline data expected in Q3 2026.
• KSI-101: A bispecific therapy for macular edema secondary to inflammation (MESI). Phase 3 PEAK and PINNACLE studies are actively enrolling. Topline data expected in Q4 2026 and Q2 2027, respectively.

Risks and Contingencies:

• Capital Requirements: Failure to secure additional financing could force the company to pause, scale back, or discontinue development programs.
• Regulatory Uncertainty: No assurance that product candidates will receive regulatory approval. Previous trials (DAZZLE, GLEAM, GLIMMER) failed to meet primary efficacy endpoints, though development resumed following positive data from other studies.
• Manufacturing: Reliance on third-party manufacturers (Lonza) and single-source suppliers for raw materials creates supply chain risks.
• Competition: Significant competition from established anti-VEGF therapies (e.g., aflibercept, faricimab) and biosimilars.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline management estimates for current cash sufficiency and the status of any ongoing fundraising efforts.
• BLA Submission Timing: Confirm the specific target date for the Biologics License Application (BLA) submission for Zenkuda in 2026 and the FDA's feedback on the inclusion of DAYBREAK data.
• DAYBREAK Trial Design: Review the specific dosing protocols and AI-driven assessment tools used in the DAYBREAK trial to understand potential regulatory hurdles regarding the "treat-to-dryness" approach.
• Sublease Impact: Assess the long-term financial impact of the sublease agreement on the Palo Alto facility and any remaining lease obligations.
• Patent Landscape: Evaluate the status of patent applications for the ABC Platform and specific product candidates, particularly regarding potential third-party infringement claims mentioned in the risk factors.